The Problem: Pharma
No Profits,
No New Drugs.
Antimicrobials are uniquely difficult to profit from. They cost over $1 billion to develop, are used sparingly to slow resistance, and are kept as a last resort.
Unlike chronic or lifestyle drugs, there’s insufficient return on investment, so most major pharmaceutical companies have exited antibiotic R&D altogether.
The Problem: Funding
A System
Designed to Fail.
Public and philanthropic funding for AMR is a fraction of what’s needed. Less than 1% of global health research goes to antimicrobial resistance.
Even small biotechs that succeed in creating new antibiotics often collapse commercially. The existing funding ecosystem isn’t built to support long-term, high-impact innovation in this space.
The “Valley of Death" refers to the significant gap and hurdles faced when transitioning biomedical research from the laboratory to clinical applications, commercialisation, and widespread use.
The failure to act on AMR has real consequences. Common infections become life threatening, transplants riskier, and everyday activities more dangerous. In a worst-case future, social contact is limited, public spaces are unsafe, and trust in basic safety breaks down.
The Way Forward Isn't Just Scientific, It's Systemic.
Even as expertise leaves the field, we must continue developing new solutions and building the tools that support them, by filling data gaps, advancing AI models, and driving innovation forward.
To sustain this momentum, we need to continually replenish the funding that powers these efforts through models that go beyond governments and corporations, enabling global, collective support.
The Solution: MicroDAO
Meet MicroDAO: The First Line of Defence Against AMR.
MicroDAO is a decentralised, community-driven collective funding antimicrobial innovation. It combines on-chain governance, transparent incentives, and global coordination to support the researchers, tools, and breakthroughs that traditional systems overlook.
We are rebuilding the model, so science can keep up with resistance.
Explore AMR Impact
Why does AMR matter? See how drug resistance is already reshaping global health and how MicroDAO is leading a new approach to tackle it.
Learn Web3
Web3 can unlock the future of science. Explore how decentralisation, tokens, and DAOs are transforming how research gets done.
Visit Blog
Get fresh insights on AMR, decentralised science, and MicroDAO’s latest work.
Get MICRO
Fuel the movement. Support sustainable, open innovation against AMR and its decentralised future.
